It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
During intracellular infection, T follicular helper (TFH) and T helper 1 (TH1) cells promote humoral and cell-mediated responses, respectively. Another subset, CD4-cytotoxic T lymphocytes (CD4-CTLs), eliminate infected cells via functions typically associated with CD8+ T cells. The mechanisms underlying differentiation of these populations are incompletely understood. Here, we identify the transcription factor Aiolos as a reciprocal regulator of TFH and CD4-CTL programming. We find that Aiolos deficiency results in downregulation of key TFH transcription factors, and consequently reduced TFH differentiation and antibody production, during influenza virus infection. Conversely, CD4-CTL programming is elevated, including enhanced Eomes and cytolytic molecule expression. We further demonstrate that Aiolos deficiency allows for enhanced IL-2 sensitivity and increased STAT5 association with CD4-CTL gene targets, including Eomes, effector molecules, and IL2Ra. Thus, our collective findings identify Aiolos as a pivotal regulator of CD4-CTL and TFH programming and highlight its potential as a target for manipulating CD4+ T cell responses.
The regulation and direction of CD4+ T cells into phenotypic and functional lineages is coordinated by a complex set of mechanisms. Here the authors show a role for Aiolos as a regulator of the CD4+ cytotoxic and T follicular helper lineages.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); Biomedical Sciences Graduate Program, Columbus, USA (GRID:grid.261331.4)
2 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
3 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); Biomedical Sciences Graduate Program, Columbus, USA (GRID:grid.261331.4); Medical Scientist Training Program, Columbus, USA (GRID:grid.261331.4)
4 Biomedical Sciences Graduate Program, Columbus, USA (GRID:grid.261331.4); The Ohio State University College of Medicine and Wexner Medical Center, Department of Pathology, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
5 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University College of Veterinary Medicine, Combined Anatomic Pathology Residency/PhD Program, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
6 Emory University School of Medicine, Department of Microbiology and Immunology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
7 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University College of Medicine and Wexner Medical Center, Infectious Diseases Institute, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
8 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, USA (GRID:grid.413944.f) (ISNI:0000 0001 0447 4797)
9 The Ohio State University College of Medicine and Wexner Medical Center, Department of Pathology, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, USA (GRID:grid.413944.f) (ISNI:0000 0001 0447 4797)
10 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University College of Medicine and Wexner Medical Center, Infectious Diseases Institute, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, USA (GRID:grid.413944.f) (ISNI:0000 0001 0447 4797)